$148 Million is the total value of First Light Asset Management, LLC's 68 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVS | NOVARTIS A Gsponsored adr | $550,000 | +6.6% | 6,070 | 0.0% | 0.37% | +1.4% | |
| MYL | MYLAN INC | $504,000 | +5.7% | 9,775 | 0.0% | 0.34% | +0.6% | |
| HUM | HUMANA INC | $452,000 | +13.3% | 3,540 | 0.0% | 0.30% | +7.8% | |
| V107SC | WELLPOINT INC | $441,000 | +8.1% | 4,095 | 0.0% | 0.30% | +2.8% | |
| AET | AETNA INC NEW | $423,000 | +8.2% | 5,215 | 0.0% | 0.28% | +2.9% | |
| AZN | ASTRAZENECA PLCsponsored adr | $422,000 | +14.4% | 5,680 | 0.0% | 0.28% | +8.8% | |
| STJ | ST JUDE MED INC | $419,000 | +5.8% | 6,055 | 0.0% | 0.28% | +0.4% | |
| BMY | BRISTOL MYERS SQUIBB CO | $402,000 | -6.7% | 8,290 | 0.0% | 0.27% | -11.1% | |
| JNJ | JOHNSON & JOHNSON | $400,000 | +6.7% | 3,820 | 0.0% | 0.27% | +1.1% | |
| MRK | MERCK & CO INC NEW | $382,000 | +1.9% | 6,610 | 0.0% | 0.26% | -3.4% | |
| CFN | CAREFUSION CORP | $343,000 | +10.3% | 7,730 | 0.0% | 0.23% | +5.0% | |
| LLY | LILLY ELI & CO | $342,000 | +5.9% | 5,495 | 0.0% | 0.23% | +0.4% | |
| STE | STERIS CORP | $339,000 | +12.3% | 6,330 | 0.0% | 0.23% | +6.5% | |
| UTHR | UNITED THERAPEUTICS CORP DEL | $338,000 | -5.8% | 3,820 | 0.0% | 0.23% | -10.2% | |
| BDX | BECTON DICKINSON & CO | $331,000 | +1.2% | 2,795 | 0.0% | 0.22% | -3.9% | |
| PFE | PFIZER INC | $312,000 | -7.7% | 10,520 | 0.0% | 0.21% | -12.1% | |
| MYGN | MYRIAD GENETICS INC | $304,000 | +13.9% | 7,820 | 0.0% | 0.20% | +8.5% | |
| SNY | SANOFIsponsored adr | $302,000 | +1.7% | 5,680 | 0.0% | 0.20% | -3.3% | |
| A | AGILENT TECHNOLOGIES INC | $294,000 | +2.8% | 5,120 | 0.0% | 0.20% | -2.5% | |
| CYH | COMMUNITY HEALTH SYS INC NEW | $279,000 | +15.8% | 6,145 | 0.0% | 0.19% | +9.9% | |
| AMGN | AMGEN INC | $276,000 | -3.8% | 2,330 | 0.0% | 0.19% | -8.4% | |
| BIO | BIO RAD LABS INCcl a | $201,000 | -6.5% | 1,675 | 0.0% | 0.14% | -11.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-06-10 |
| SC 13G/A | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.